Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research Institute, is the principal investigator and international coordinator of a controlled phase 2 drug study that, for the first time in 20 years, is achieving positive results for cognitive complications in Parkinson’s disease. Sant Pau Hospital has also participated as a patient recruitment centre for the study.
